Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Next Science Ltd ( (AU:NXS) ).
Next Science Limited has announced an addendum to its Notice of General Meeting, detailing a change in the purchaser of its assets from Demetra Holding S.p.A to OSARTIS GmbH, a portfolio company of Demetra. This change does not affect the fairness and reasonableness of the proposed transaction as confirmed by the Independent Expert’s Report. The meeting details remain unchanged, and shareholders can alter their proxy votes online if needed.
The most recent analyst rating on (AU:NXS) stock is a Buy with a A$0.40 price target. To see the full list of analyst forecasts on Next Science Ltd stock, see the AU:NXS Stock Forecast page.
More about Next Science Ltd
Next Science is a medical technology company based in Sydney, Australia, with a research and development center in Jacksonville, Florida, USA. Founded in 2012, the company focuses on developing and commercializing its proprietary XBIO™ technology aimed at reducing the impact of infections in human health.
YTD Price Performance: 26.09%
Average Trading Volume: 526,858
Technical Sentiment Signal: Sell
Current Market Cap: A$42.43M
See more insights into NXS stock on TipRanks’ Stock Analysis page.